Nuvation Bio Inc. (NUVB)
NYSE · Healthcare · Biotechnology
$4.95−3.70%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.7B
- 52-week range
- $3.36 – $9.75
- 52-week change
- +40.44%
- EPS (trailing)
- −$0.44
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $62.9M (+698.96%)
- Net income
- −$205M
- Operating margin
- −338.7%
- Diluted EPS
- −$0.60
From the company’s annual report on SEC EDGAR.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Headquarters: New York, United States · 305 employees · nuvationbio.com